Health care providers are advised to use the tables and the notes together.
* Recommendations for routine use of vaccines in adults are developed by Advisory Committee on Immunization Practices (ACIP), a federal advisory committee chartered to provide expert external advice and guidance to the CDC Director on use of vaccines and related agents for the control of vaccinepreventable diseases in the civilian population of the United States.
Recommendations for routine use of vaccines in adults are harmonized to the greatest extent possible with recommendations made by the American Academy of Family Physicians (AAP) and the American College of Obstetricians and Gynecologists (ACOG 
Changes in the 2020 Adult Immunization Schedule
Changes in the 2020 adult immunization schedule for persons aged ≥19 years include new or revised recommendations for hepatitis A vaccine (HepA) (2); human papillomavirus vaccine (HPV) (3); influenza vaccine (4); serogroup B meningococcal vaccine (MenB); pneumococcal vaccine (5); and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) (6) . Following are the changes to the cover page, Table 1 , Table 2 , and Notes.
Cover page
• Trademark symbols (®) were added to all vaccine trade names.
• PedvaxHIB was added to the table of trade names for
Haemophilus influenzae type b vaccine. • The footnote on the cover page has been edited and now reads "Do not restart or add doses to vaccine series if there are extended intervals between doses." The red box has been edited and now reads "Not recommended/contraindicated -vaccine should not be administered." The text appearing in the red bars has been changed from "Contraindicated" to "Not Recommended."
Notes
• Edits have been made throughout the Notes section to harmonize language between the child/adolescent immunization schedule and the adult immunization schedule, where possible. • A new subsection entitled "Shared Clinical Decision-Making" was added for each vaccine that includes this new ACIP recommendation (e.g., for HPV, PCV13, and MenB). should not be used and minor edits to the guidance for persons with a history of Guillain-Barré syndrome. • Measles, mumps, and rubella: The note was revised to clarify recommendations for health care personnel, with a separate bullet for personnel born in 1957 or later with no evidence of immunity and for health care personnel born before 1957 with no evidence of immunity. • Meningococcal: The note was revised to include the use of the complement inhibitor ravulizumab as an indication for MenB administration in these patients. A shared clinical decision-making subsection was added that includes a bullet for adolescents and young adults aged 16-23 years who are not at increased risk for meningococcal disease. Under the "Special situations" section, the recommendation to administer a booster dose of MenB 1 year after the primary series and to revaccinate every 2-3 years if the risk remains was added. • Pneumococcal: The note has been updated to reflect the updated recommendations for vaccination of immunocompetent (defined as adults without an immunocompromising condition, cerebrospinal fluid leak, or cochlear implants) adults aged ≥65 years. One dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) is still recommended. Shared clinical decision-making is recommended regarding administration of PCV13 to immunocompetent persons aged ≥65 years. • Tetanus, diphtheria, and pertussis: The note has been updated to indicate that Td or Tdap may be used in situations where only Td vaccine was indicated for the decennial tetanus, diphtheria, and pertussis booster vaccination, tetanus prophylaxis for wound management, and catch-up vaccination. • Varicella: The note has been updated to indicate that vaccination may be considered for persons with HIV infection without evidence of varicella immunity who have CD4 counts ≥200 cells/µL.
